Tumour budding is a novel marker in breast cancer: the clinical application and future prospects

KEY MESSAGES: Currently, tumour budding is a poor prognosis for various solid tumours, also in breast cancer. Tumour budding is based on epithelial-mesenchymal transition and tumour microenvironment factors and is presumed to be an early step in the metastatic process. Breast cancer tumour budding s...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Ting, Bao, Hui, Meng, Yu-hua, Zhu, Jian-lin, Chu, Xiao-dong, Chu, Xiao-li, Pan, Jing-hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9103277/
https://www.ncbi.nlm.nih.gov/pubmed/35535687
http://dx.doi.org/10.1080/07853890.2022.2070272
Descripción
Sumario:KEY MESSAGES: Currently, tumour budding is a poor prognosis for various solid tumours, also in breast cancer. Tumour budding is based on epithelial-mesenchymal transition and tumour microenvironment factors and is presumed to be an early step in the metastatic process. Breast cancer tumour budding still needs multi-centre experiments. We summarize the current research on breast cancer tumour budding, analyse the method of discriminating breast cancer tumour budding and explore the prognostic role and mechanism in breast cancer.

Ejemplares similares